Key result
A review of hematologic pharmacology, including fibrinolytic agents, thrombin inhibitors, and antiplatelet agents, highlights their importance in managing ST-segment elevation myocardial infarction.
Answers are grounded in this paper and cite their sources.
This review highlights the critical role of hematologic pharmacology, including fibrinolytics and antiplatelets, in managing ST-segment elevation myocardial infarction.
Drugs that work on the hematologic system play an important role in helping to limit the morbidity and mortality that can be associated with an acute coronary syndrome. The pharmacology of the fibrinolytic agents, thrombin inhibitors, and antiplatelet agents is described. A case study of a woman having an ST-segment elevation myocardial infarction is reviewed to highlight the importance of drugs that work on the hematologic system.
No takes yet. Share an insight, caveat, or question.
Stacy H. James (2012) conducted a review in ST-segment elevation myocardial infarction (n=1). Hematologic pharmacology (fibrinolytic agents, thrombin inhibitors, and antiplatelet agents) was evaluated. A review of hematologic pharmacology, including fibrinolytic agents, thrombin inhibitors, and antiplatelet agents, highlights their importance in managing ST-segment elevation myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: